The endocannabinoid system and its therapeutic exploitation (original) (raw)

• Adams, I. B. & Martin, B. R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585–1614 (1996).
  Article CAS PubMed Google Scholar
• Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
  Google Scholar
• Williamson, E. M. & Evans, F. J. Cannabinoids in clinical practice. Drugs 60 1303–1314 (2000).
  Article CAS PubMed Google Scholar
• Gaoni, Y. & Mechoulam, R. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86, 1646–1647 (1964). The long-awaited conclusive chemical characterization of THC, the major psychoactive constituent of Cannabis.
  Article CAS Google Scholar
• Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137–143 (2003).
  Article PubMed Google Scholar
• Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34, 605–613 (1988). The first sound evidence for the existence of specific binding sites for THC.
  CAS PubMed Google Scholar
• Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564 (1990).
  Article CAS PubMed Google Scholar
• Mechoulam, R. & Hanus, L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem. Phys. Lipids 121, 35–43 (2002).
  Article CAS PubMed Google Scholar
• Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61–65 (1993).
  Article CAS PubMed Google Scholar
• Di Marzo, V. & Fontana, A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot. Essent. Fatty Acids 53, 1–11 (1995).
  Article CAS PubMed Google Scholar
• Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946–1949 (1992). The study reporting the identification of the first endocannabinoid, anandamide.
  Article CAS PubMed Google Scholar
• Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83–90 (1995).
  Article CAS PubMed Google Scholar
• Sugiura, T. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Commun. 215, 89–97 (1995).
  Article CAS Google Scholar
• McAllister, S. D. & Glass, M. CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot. Essent. Fatty Acids 66, 161–171 (2002).
  Article CAS PubMed Google Scholar
• Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A. & Bisogno, T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66, 377–391 (2002).
  Article CAS PubMed Google Scholar
• Piomelli, D. The molecular logic of endocannabinoid signalling. Nature Rev. Neurosci. 4, 873–884 (2003).
  Article CAS Google Scholar
• De Petrocellis, L., Cascio, M. G. & Di Marzo, V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol. 141, 765–774 (2004).
  Article CAS PubMed Google Scholar
• Pertwee, R. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129–180 (1997).
  CAS PubMed Google Scholar
• Howlett, A. C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35, 607–634 (1995).
  Article CAS PubMed Google Scholar
• Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521–528 (1998).
  Article CAS PubMed Google Scholar
• Schlicker, E. & Kathmann, M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22, 565–572 (2001).
  Article CAS PubMed Google Scholar
• Wilson, R. I. & Nicoll, R. A. Endocannabinoid signaling in the brain. Science 296, 678–682 (2002).
  Article CAS PubMed Google Scholar
• Freund, T. F., Katona, I. & Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017–1066 (2003).
  Article CAS PubMed Google Scholar
• Parolaro, D. & Rubino, T. Is cannabinoid transmission involved in rewarding properties of drugs of abuse? Br. J. Pharmacol. 136, 1083–1084 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Gerdeman, G. L., Partridge, J. G., Lupica, C. R. & Lovinger, D. M. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci. 26, 184–192 (2003).
  Article CAS PubMed Google Scholar
• Iversen, L. & Chapman, V. Cannabinoids: a real prospect for pain relief? Curr. Opin. Pharmacol. 2, 50–55 (2002).
  Article CAS PubMed Google Scholar
• Randall, M. D., Harris, D., Kendall, D. A. & Ralevic, V. Cardiovascular effects of cannabinoids. Pharmacol. Ther. 95, 191–202 (2002).
  Article CAS PubMed Google Scholar
• Di Carlo, G. & Izzo, A. A. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert. Opin. Investig. Drugs 12, 39–49 (2003).
  Article CAS PubMed Google Scholar
• Schmid, K., Niederhoffer, N. & Szabo, B. Analysis of the respiratory effects of cannabinoids in rats. Naunyn Schmiedebergs Arch. Pharmacol. 368, 301–308 (2003).
  Article CAS PubMed Google Scholar
• Wenger, T. & Moldrich, G. The role of endocannabinoids in the hypothalamic regulation of visceral function. Prostaglandins Leukot. Essent. Fatty Acids 66, 301–307 (2002).
  Article CAS PubMed Google Scholar
• Park, B., McPartland, J. M. & Glass, M. Cannabis, cannabinoids and reproduction. Prostaglandins Leukot. Essent. Fatty Acids 70, 189–197 (2004).
  Article CAS PubMed Google Scholar
• Klein, T. W. et al. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486–496 (2003).
  Article CAS PubMed Google Scholar
• Guzman, M., Sanchez, C. & Galve-Roperh, I. Cannabinoids and cell fate. Pharmacol. Ther. 95, 175–184 (2002).
  Article CAS PubMed Google Scholar
• Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
  Google Scholar
• Marsicano, G. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84–88 (2003). An important study, together with reference 37, exemplifying the 'on-demand' character of endocannabinoid-mediated protective functions.
  Article CAS PubMed Google Scholar
• Kirkham, T. C., Williams, C. M., Fezza, F. & Di Marzo, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 136, 550–557 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Marsicano, G. et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530–534 (2002).
  Article CAS PubMed Google Scholar
• Walker, J. M., Huang, S. M., Strangman, N. M., Tsou, K. & Sanudo-Pena, M. C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl Acad. Sci. USA 96, 12198–12203 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Di Marzo, V. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822–825 (2001). The first study pointing to a role for the endocannabinoids as orexigenic mediators.
  Article CAS PubMed Google Scholar
• Cota, D. et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423–431 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Schabitz, W. R. et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 33, 2112–2114 (2002).
  Article CAS PubMed Google Scholar
• Parmentier-Batteur, S., Jin, K., Mao, X. O., Xie, L. & Greenberg, D. A. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 22, 9771–9775 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Panikashvili, D. et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527–531 (2001).
  Article CAS PubMed Google Scholar
• Di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R. & Brotchie, J. M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432–1438 (2000).
  Article CAS PubMed Google Scholar
• Maccarrone, M. et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85, 1018–1025 (2003).
  Article CAS PubMed Google Scholar
• Baker, D. et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15, 300–302 (2001). The first example of the use of inhibitors of endocannabinoid inactivation as potential therapeutic agents.
  Article CAS PubMed Google Scholar
• Baker, D. et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84–87 (2000).
  Article CAS PubMed Google Scholar
• Mazzola, C., Micale, V. & Drago, F. Amnesia induced by β-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477, 219–225 (2003).
  Article CAS PubMed Google Scholar
• Silverdale, M. A., McGuire, S., McInnes, A., Crossman, A. R. & Brotchie, J. M. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 169, 400–406 (2001).
  Article CAS PubMed Google Scholar
• Berrendero, F. et al. Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41, 195–202 (2001).
  Article CAS PubMed Google Scholar
• Benito, C. et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136–11141 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Lastres-Becker, I. et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 12, 2125–2129 (2001).
  Article CAS PubMed Google Scholar
• Denovan-Wright, E. M. & Robertson, H. A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705–713 (2000).
  Article CAS PubMed Google Scholar
• Glass, M., Faull, R. L. & Dragunow, M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56, 523–527 (1993). The first report of the possible involvement of cannabinoid receptors in a neurodegenerative disorder.
  Article CAS PubMed Google Scholar
• Bensaid, M. et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908–914 (2003).
  Article CAS PubMed Google Scholar
• Ravinet Trillou, C. et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R345–R353 (2003).
  Article PubMed Google Scholar
• Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M. & Soubrie, P. CB1 cannabinoid receptor knockout in mice leads to leannes, resistence to diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat. Metab. Disord. 28, 640–648 (2004).
  Article CAS PubMed Google Scholar
• Wagner, J. A. et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518–521 (1997). Possibly the first example of a pathological condition involving an altered endocannabinoid system.
  Article CAS PubMed Google Scholar
• Varga, K., Wagner, J. A., Bridgen, D. T. & Kunos, G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12, 1035–1044 (1998).
  Article CAS PubMed Google Scholar
• Batkai, S. et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Med. 7, 827–832 (2001).
  Article CAS PubMed Google Scholar
• Wagner, J. A. et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38, 2048–2054 (2001).
  Article CAS PubMed Google Scholar
• Izzo, A. A. et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134, 563–570 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Izzo, A. A. et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125, 765–774 (2003). A typical example of a protective role played 'on demand' by endocannabinoids in a peripheral organ.
  Article CAS PubMed Google Scholar
• Mascolo, N. et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J. 16, 1973–1975 (2002).
  Article CAS PubMed Google Scholar
• Massa, F. et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202–1209 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, H. et al. Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc. Natl Acad. Sci. USA 100, 14914–14919 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Maccarrone, M. et al. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355, 1326–1329 (2000). The first human study pointing to the possible pathological consequences of over-active endocannabinoid signalling.
  Article CAS PubMed Google Scholar
• Maccarrone, M. et al. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol. Hum. Reprod. 8, 188–195 (2002).
  Article CAS PubMed Google Scholar
• Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677–687 (2003).
  Article CAS PubMed Google Scholar
• Schmid, P. C., Wold, L. E., Krebsbach, R. J., Berdyshev, E. V. & Schmid, H. H. Anandamide and other N-acylethanolamines in human tumors. Lipids 37, 907–912 (2002).
  Article CAS PubMed Google Scholar
• Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784–5789 (2001).
  CAS PubMed Google Scholar
• De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl Acad. Sci. USA 95, 8375–8380 (1998). The antiproliferative effects of the endocannabinoids against cancer cells in vitro were examined for the first time in this study. Together with reference 73, this marked the beginning of studies on the possible anticancer function of the endocannabinoid system.
  Article CAS PubMed PubMed Central Google Scholar
• Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med. 6, 313–319 (2000).
  Article CAS PubMed Google Scholar
• Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15, 2745–2747 (2001).
  Article CAS PubMed Google Scholar
• Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43–50 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 17, 1771–1773 (2003).
  Article CAS PubMed Google Scholar
• Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2 August 2004 (doi:10-1096/fj.04-1754fje).
• Alberich Jorda, M. et al. The peripheral cannabinoid receptor CB2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 104, 526–534 (2004).
  Article PubMed CAS Google Scholar
• Cravatt, B. F. & Lichtman, A. H. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. 7, 469–475 (2003).
  Article CAS PubMed Google Scholar
• Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686–691 (1994). First proof that the endocannabinoid anandamide is an endogenous mediator in that it can be produced by neurons in an activity-dependent manner and inactivated by both neurons and astrocytes.
  Article CAS PubMed Google Scholar
• Di Marzo, V., De Petrocellis, L. Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316, 977–984 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322, 671–677 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773–778 (1997).
  Article CAS PubMed Google Scholar
• Schmid, P. C., Reddy, P. V., Natarajan, V. & Schmid, H. H. Metabolism of _N_-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258, 9302–9306 (1983).
  Article CAS PubMed Google Scholar
• Okamoto, Y., Morishita, J., Tsuboi, K., Tonai, T. & Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298–5305 (2004). Cloning of the major enzyme catalysing anandamide biosynthesis.
  Article CAS PubMed Google Scholar
• Sugiura, T. et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of _N_-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240, 53–62 (1996).
  Article CAS PubMed Google Scholar
• Cadas, H., di Tomaso, E. & Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid precursor, _N_-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17, 1226–1242 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Bisogno, T. et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163, 463–468 (2003). Reports the cloning of the first enzymes catalysing the biosynthesis of an endocannabinoid, 2-arachidonoylglycerol.
  Article CAS PubMed PubMed Central Google Scholar
• Williams, E. J., Walsh, F. S. & Doherty, P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 160, 481–486 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Fernandez-Ruiz, J., Berrendero, F., Hernandez, M. L. & Ramos, J. A. The endogenous cannabinoid system and brain development. Trends Neurosci. 23, 14–20 (2000).
  Article CAS PubMed Google Scholar
• Lichtman, A. H., Shelton, C. C., Advani, T. & Cravatt, B. F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109, 319–327 (2004). An important study confirming conclusively that FAAH can be targeted for the development of new antihyperalgesic drugs.
  Article CAS PubMed Google Scholar
• Clement, A. B., Hawkins, E. G., Lichtman, A. H. & Cravatt, B. F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. 23, 3916–3923 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Sipe, J. C., Chiang, K., Gerber, A. L., Beutler, E. & Cravatt, B. F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA 99, 8394–8399 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ligresti, A. et al. Further evidence for the specific process for the membrane transport of anandamide. Biochem. J. 380, 265–272 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hillard, C. J., Edgemond, W. S., Jarrahian, A. & Campbell, W. B. Accumulation of _N_-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69, 631–638 (1997).
  Article CAS PubMed Google Scholar
• Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094–1097 (1997).
  Article CAS PubMed Google Scholar
• Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L. & Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272, 3315–3323 (1997).
  Article CAS PubMed Google Scholar
• Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C. & Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298, 1793–1796 (2002).
  Article CAS PubMed Google Scholar
• Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. Proc. Natl Acad. Sci. USA 100, 4269–4274 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Ortar, G., Ligresti, A., De Petrocellis, L., Morera, E. & Di Marzo, V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65, 1473–1481 (2003).
  Article CAS PubMed Google Scholar
• Lopez-Rodriguez, M. L. et al. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 46, 1512–1522 (2003).
  Article CAS PubMed Google Scholar
• Fegley, D. et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl Acad. Sci. USA (in the press).
• Hillard, C. J. & Jarrahian, A. Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol. 140, 802–808 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Cravatt, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83–87 (1996). Reports the cloning of the first 'endocannabinoid enzyme', FAAH, a potential therapeutic target for analgesic and anxiolytic compounds.
  Article CAS PubMed Google Scholar
• Cravatt, B. F. et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 98, 9371–9376 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, B. R. et al. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294, 1209–1218 (2000).
  CAS PubMed Google Scholar
• Kathuria, S. et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med. 9, 76–81 (2003).
  Article CAS PubMed Google Scholar
• Leung, D., Hardouin, C., Boger, D. L. & Cravatt, B. F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nature Biotechnol. 21, 687–691 (2003).
  Article CAS Google Scholar
• Karlsson, M., Contreras, J. A., Hellman, U., Tornqvist, H. & Holm, C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J. Biol. Chem. 272, 27218–27223 (1997).
  Article CAS PubMed Google Scholar
• Dinh, T. P. et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad. Sci. USA 99, 10819–10824 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Ben-Shabat, S. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353, 23–31 (1998).
  Article CAS PubMed Google Scholar
• Hanus, L. et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl Acad. Sci. USA 96, 14228–14233 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Ibrahim, M. M. et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl Acad. Sci. USA 100, 10529–10533 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627–634 (2002).
  Article CAS PubMed Google Scholar
• Rinaldi-Carmona, M. et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240–244 (1994). Describes the development of the first selective cannabinoid CB 1 -receptor antagonist, rimonabant, which is now in Phase III clinical trials being tested as an anti-obesity agent and against nicotine dependence.
  Article CAS PubMed Google Scholar
• Pinto, L. et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123, 227–234 (2002).
  Article CAS PubMed Google Scholar
• Van Sickle, M. D. et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121, 767–774 (2001).
  Article CAS PubMed Google Scholar
• Darmani, N. A. Δ(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).
  Article CAS PubMed Google Scholar
• Cichewicz, D. L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74, 1317–1324 (2004).
  Article CAS PubMed Google Scholar
• Naef, M. et al. The analgesic effect of oral Δ-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105, 79–88 (2003).
  Article CAS PubMed Google Scholar
• Di Marzo, V. et al. Neurobehavioral activity in mice of _N_-vanillyl-arachidonyl-amide. Eur. J. Pharmacol. 406, 363–374 (2000).
  Article CAS PubMed Google Scholar
• Di Marzo, V. et al. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun. 281, 444–451 (2001).
  Article CAS PubMed Google Scholar
• Brooks, J. W. et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. Eur. J. Pharmacol. 439, 83–92 (2002).
  Article CAS PubMed Google Scholar
• Melck, D. et al. Unsaturated long-chain _N_-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res. Commun. 262, 275–284 (1999).
  Article CAS PubMed Google Scholar
• Wiley, J. L. et al. Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity. Pharmacology 66, 89–99 (2002).
  Article CAS PubMed Google Scholar
• Ross, R. A. et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 126, 665–672 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• De Vry, J. M. et al. 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl 4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and anti-allodynic effects. J. Pharmacol. Exp. Ther. 310, 620–632 (2004).
  Article CAS PubMed Google Scholar
• Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
  Google Scholar
• Wade, D. T., Robson, P., House, H., Makela, P. & Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17, 21–29 (2003).
  Article PubMed Google Scholar
• Cannabis-based medicines — GW pharmaceuticals: high CBD, high THC, medicinal cannabis — GW pharmaceuticals, THC:CBD. Drugs RD 4, 306–309 (2003).
• Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
  CAS PubMed Google Scholar
• Burstein, S. H. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr. Pharm. Des. 6, 1339–1345 (2000).
  Article CAS PubMed Google Scholar
• Sumariwalla, P. F. et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50, 985–998 (2004).
  Article CAS PubMed Google Scholar
• Bisogno, T. et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845–852 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Feigenbaum, J. J. et al. Nonpsychotropic cannabinoid acts as a functional _N_-methyl-D-aspartate receptor blocker. Proc. Natl Acad. Sci. USA 86, 9584–9587 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, J., Li, H., Burstein, S. H., Zurier, R. B. & Chen, J. D. Activation and binding of peroxisome proliferator-activated receptor-γ by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 63, 983–992 (2003).
  Article CAS PubMed Google Scholar
• Lange, J., Kruse, C., Tipker, J., Tulp, M. & van Vliet, B. (Solvay Pharmaceuticals) 4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. WO0170700 (2001).
• Makrijannis, A. & Deng, H. (Univ. Connecticut) Cannabimimetic indole derivatives. WO0128557 (2001).
• Makrijannis, A. & Deng, H. (Univ. Connecticut) Retro-anandamides, high affinity and stability cannabinoid receptor ligands. WO0128498 (2001).
• Mauler, F. et al. BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev. 9, 343–358 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Rinaldi-Carmona, M. et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644–650 (1998).
  CAS PubMed Google Scholar
• Iwamura, H., Suzuki, H., Ueda, Y., Kaya, T. & Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther. 296, 420–425 (2001).
  CAS PubMed Google Scholar
• Pertwee, R. G. et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol. 129, 1577–1584 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Zajicek, J. et al. UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362, 1517–1526 (2003). The first very large controlled clinical study with THC and Cannabis extract as potential treatments for a human disorder.
  Article CAS PubMed Google Scholar
• Muller-Vahl, K. R. et al. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64, 459–465 (2003).
  Article PubMed Google Scholar
• Sieradzan, K. A. et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57, 2108–2111 (2001).
  Article CAS PubMed Google Scholar
• Fox, S. H., Kellett, M., Moore, A. P., Crossman, A. R. & Brotchie, J. M. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17, 145–149 (2002).
  Article PubMed Google Scholar
• Porcella, A., Maxia, C., Gessa, G. L. & Pani, L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13, 409–412 (2001).
  Article CAS PubMed Google Scholar
• Buggy, D. J. et al. Lack of analgesic efficacy of oral Δ-9-tetrahydrocannabinol in postoperative pain. Pain 106, 169–172 (2003).
  Article CAS PubMed Google Scholar
• Abrams, D. I. et al. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 139, 258–266 (2003).
  Article CAS PubMed Google Scholar
• Grant, I., Gonzalez, R., Carey, C. L., Natarajan, L. & Wolfson, T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J. Int. Neuropsychol. Soc. 9, 679–689 (2003).
  Article CAS PubMed Google Scholar
• James, J. S. Marijuana safety study completed: weight gain, no safety problems. AIDS Treat. News 348, 3–4 (2000).
  Google Scholar
• Tramer, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323, 16–21 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Karst, M. et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290, 1757–1762 (2003).
  Article CAS PubMed Google Scholar
• Knoller, N. et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit. Care Med. 30, 548–554 (2002).
  Article CAS PubMed Google Scholar
• Di Marzo, V. et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258–267 (1999).
  Article CAS PubMed Google Scholar
• Chevaleyre, V. & Castillo, P. E. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38, 461–472 (2003). The first study pointing to a possible functional difference between 2-AG and anandamide in the modulation of synaptic neurotransmission.
  Article CAS PubMed Google Scholar
• Egertova, M., Cravatt, B. F. & Elphick, M. R. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119, 481–496 (2003).
  Article CAS PubMed Google Scholar
• Hanus, L. et al. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl Acad. Sci. USA 98, 3662–3665 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Porter, A. C. et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301, 1020–1024 (2002).
  Article CAS PubMed Google Scholar
• Huang, S. M. et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl Acad. Sci. USA 99, 8400–8405 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, B. R., Mechoulam, R. & Razdan, R. K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65, 573–595 (1999).
  Article CAS PubMed Google Scholar
• Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 248, 515–522 (1998).
  Article CAS PubMed Google Scholar